Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
Completed
This study was designed to find the most effective and safest doses of both HYCAMTIN and CARBOPLATIN that can be given for the treatment of ovarian cancer. This study may allow researchers to determine the effectiveness of combining HYCAMTIN and CARBOPLATIN.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/21/2012
Locations: GSK Investigational Site, Milwaukee, Wisconsin
Conditions: Ovarian Cancer, Neoplasms, Ovarian
High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose chemotherapy and peripheral stem cell transplantation in treating patients with recurrent or refractory metastatic breast cancer.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/19/2012
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Breast Cancer
Phase II CT-2103/Carboplatin in Ovarian Cancer
Completed
The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/18/2008
Locations: Aurora Health Care, Inc., Milwaukee, Wisconsin
Conditions: Ovarian Neoplasm
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.
Completed
The purposes of this study are to determine the following: Whether LY900003 plus gemcitabine and carboplatin can make your tumor smaller or disappear, and for how long. If treatment with LY900003 plus gemcitabine and carboplatin can help you live longer. The safety of LY900003 plus gemcitabine and carboplatin and any side effects that might be associated with the combination of these three drugs. How LY900003 is distributed and broken down by your body when it is given with carboplatin and g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2006
Locations: Not set, Milwaukee, Wisconsin
Conditions: Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms, Neoplasms, Lung